RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Evaluation of novel particles as an inhalation system for GLP-1
Leone-Bay, A., Grant, M., Greene, S., Stowell, G., Daniels, S., Smithson, A., Villanueva, S., Cope, S., Carrera, K., Reyes, S., & Richardson, P. (2009). Evaluation of novel particles as an inhalation system for GLP-1. Diabetes, Obesity and Metabolism, 11(11), 1050-1059. https://doi.org/10.1111/j.1463-1326.2009.01096.x
The feasibility of administering native glucagon-like peptide 1 (GLP-1) as GLP-1 Technosphere (R) Inhalation Powder for diabetes therapy has been demonstrated in a rat model.
Methods
GLP-1 Technosphere Inhalation Powders containing 5, 10 and 15% GLP-1 were prepared and administered to healthy female Sprague-Dawley rats and to male Zucker diabetic obese rats. Rats received a single dose of GLP-1 Technosphere Powder by pulmonary insufflation. GLP-1 pharmacokinetic and pharmacodynamic responses were measured.
Results
Maximum circulating GLP-1 concentrations were achieved at similar to 10 min after dosing with detectable levels at 40 min. In a food consumption study, Sprague-Dawley rats receiving GLP-1 Technosphere Powder once-daily consumed less food than control rats for up to 24 h after dosing. Cumulative food consumption was decreased approximately 10% after 78 h. In an intraperitoneal glucose tolerance test, Zucker diabetic fatty rats receiving 2 mg GLP-1 Technosphere Powder (0.3 mg GLP-1) by pulmonary insufflation exhibited lower glucose concentrations and higher insulin concentrations than control rats. Pancreatic evaluations showed no differences in apoptotic index or cell proliferation of beta-cells. In addition, a dose-related increase in insulin expression within the pancreas was observed.
Conclusions
These data demonstrate the feasibility of administering native GLP-1 as GLP-1 Technosphere Inhalation Powder for diabetes therapy.